Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2021

04.05.2021 | case report

Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib

verfasst von: Olga Kuczkiewicz-Siemion, Agnieszka Dansonka-Mieszkowska, Piotr Rutkowski, Anna Klimczak, Andrzej Tysarowski, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Most gastrointestinal stromal tumors (GISTs) are associated with molecular changes in two genes, KIT and platelet-derived growth factor receptor‑α (PDGFRA). However, only 5–10% of GISTs harbor PDGFRA mutation. Most tumors carry substitution affecting codon D842 in exon 18, which entails imatinib resistance. The other substitutions in this codon are extremely rare mutations (only 13 reported cases) involving D842Y substitution. This report presents a case of gastric GIST infiltrating liver segment III in a 70-year-old man. The tumor was studied histologically, immunohistochemically, and genetically. Mutational analysis revealed PDGFRA exon 18 mutation—p.(D842Y), c.2524G > T. Diagnosis of GIST with a high risk of progression was made. Due to subsequent liver metastases, imatinib therapy was commenced, which resulted in a minor disease response at a higher dose of imatinib. Our case is a unique, comprehensive report of in vivo PDGFRA D842Y-mutated GIST partial sensitivity to imatinib.
Literatur
2.
Zurück zum Zitat Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259–69. PubMedPubMedCentral Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259–69. PubMedPubMedCentral
3.
Zurück zum Zitat Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg. 1996;33(10):817–72. CrossRef Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg. 1996;33(10):817–72. CrossRef
12.
Zurück zum Zitat Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–7. https://​doi.​org/​10.​1200/​jco.​2008.​17.​4284. CrossRefPubMed Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–7. https://​doi.​org/​10.​1200/​jco.​2008.​17.​4284. CrossRefPubMed
15.
Zurück zum Zitat Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, et al. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer. 2017;76:76–83. https://​doi.​org/​10.​1016/​j.​ejca .2017.02.007. CrossRef Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, et al. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer. 2017;76:76–83. https://​doi.​org/​10.​1016/​j.​ejca .2017.02.007. CrossRef
16.
Zurück zum Zitat Sun Q, Wu HY, Chen XY, Yang J, Ye Q, Fan XS. Signet-ring epithelioid gastrointestinal stromal tumor with rare D842Y mutation in exon 18 of PDGFRα: report of a case. Zhonghua Bing Li Xue Za Zhi. 2011;40(6):414–5. PubMed Sun Q, Wu HY, Chen XY, Yang J, Ye Q, Fan XS. Signet-ring epithelioid gastrointestinal stromal tumor with rare D842Y mutation in exon 18 of PDGFRα: report of a case. Zhonghua Bing Li Xue Za Zhi. 2011;40(6):414–5. PubMed
21.
Zurück zum Zitat Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c‑KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741–4. https://​doi.​org/​10.​1182/​blood.​v99.​5.​1741. CrossRefPubMed Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c‑KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741–4. https://​doi.​org/​10.​1182/​blood.​v99.​5.​1741. CrossRefPubMed
Metadaten
Titel
Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib
verfasst von
Olga Kuczkiewicz-Siemion
Agnieszka Dansonka-Mieszkowska
Piotr Rutkowski
Anna Klimczak
Andrzej Tysarowski
Monika Prochorec-Sobieszek
Anna Szumera-Ciećkiewicz
Publikationsdatum
04.05.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00708-2